The Ministry of Health and Welfare announced it will improve its policy to allow innovative new drugs to be listed for reimbursement through the risk-sharing assessment (RSA) track even if they are not anticancer or rare disease treatments if they demonstrate a clinical effect.

If allowed, it is expected that the scope of drugs that are applied RSA will increase, and more drugs that are not designated as rare disease may be promptly listed for reimbursement as long as they have a good effect.

Chang-Hyun Oh, Director of Pharmaceutical Benefits at the Ministry of Health and Welfare, said so at the ‘Discussions for the national measure to manage life-threatening rare diseases’ that was h